Kisqali Improves Outcomes & Survival Rates in Metastatic BC

Options

https://www.pharmacypracticenews.com/Clinical/Arti...

"SAN ANTONIO—Women with advanced breast cancer may benefit from a therapy that combines ribociclib (Kisqali, Novartis) with endocrine therapy. The combination extended progression-free survival (PFS) in women with hormone receptor–positive (HR+)/HER2– advanced breast cancer compared with endocrine therapy alone, according to a report presented at the 2018 San Antonio Breast Cancer Symposium."

Categories